
HIV drug trial will evaluate cabotegravir’s performance as a pre-exposure prophylaxis.

HIV drug trial will evaluate cabotegravir’s performance as a pre-exposure prophylaxis.

HIV resistance may necessitate more costly therapies for third-line treatment.

Global HIV incidence rates drop in some African countries.

Peer referrals for testing can locate people with undiagnosed HIV better than health care providers.

Study suggests link between diabetes and exposure to DDT, PCBs, and perfluoroalkyl.

Elevated rates of fibromyalgia found in patients with rheumatic diseases, such as psoriatic arthritis.

Patients with atrial fibrillation and end-stage renal disease may face a greater risk of all-cause bleeding without reducing strokes in Warfarin.

Few prior studies have evaluated the relative effectiveness of earlier and later lines of TNF therapy in psoriatic arthritis.

Few prior studies have evaluated the relative effectiveness of earlier and later lines of TNFi therapy in psoriatic arthritis.

Study evaluates whether etanercept monotherapy treats psoriatic arthritis as effectively as the combination of etanercept and methotrexate.

Study evaluates whether smoking cigarettes worsens clinical damage in PsA patients as it does in rheumatoid arthritis and ankylosing spondylitis.

Antiarrhythmic drugs do not impact long-term rate of recurrent atrial fibrillation.

Duration of psoriasis at baseline impacts the odds of developing erosion in psoriatic arthritis.

Tofacitinib may offer an effective oral option for patients with psoriatic arthritis.

Study finds 15.5% of all psoriasis patients had undiagnosed psoriatic arthritis.

Study compares Zenpep with Creon for efficacy and safety in the treatment of adolescents and adults with cystic fibrosis-associated exocrine pancreatic insufficiency.

Etanercept shows sustained efficacy treating the symptoms of 3 juvenile idiopathic arthritis categories.

Psoriatic arthritis patients are more likely to develop conditions such as hypertension, diabetes, obesity, and dyslipidemia.

Annual per patient cost for pancreatic therapies and medications found to create significant financial burden.

Higher risk of serious infection found with adalimumab and infliximab compared with nonmethotrexate and nonbiologic therapies.

Patients with inflammatory rheumatic diseases may not need more frequent vaccinations.

Researchers compare efficacy and side effects of different psoriatic arthritis treatment options.

Researchers compare efficacy and side effects of different psoriatic arthritis treatment options.

Research suggests psychosocial comorbidities and elevated risk of atherosclerosis in RA patients.

Research compares multidimensional approaches with uni-dimensional interventions.

Prescription drugs costs for patients with psoriatic arthritis tended to be higher than comparable costs for ankylosing spondylitis.

Balanced approach needed to better discriminate between high and low disease activity.

Patients who received golimumab and methotrexate reported larger improvements than monotherapy patients.

Significant weight loss found to reduce disease burden in psoriatic arthritis patients.

Combination of risk factors and PsA disease activity found increase dangers of cardiovascular disease.

Published: July 6th 2015 | Updated:

Published: August 21st 2015 | Updated:

Published: September 10th 2015 | Updated:

Published: September 29th 2015 | Updated:

Published: October 15th 2015 | Updated:

Published: October 30th 2015 | Updated: